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Abstract
Background: Genetic mosaicism is only detected occasionally when there are no obvious health or developmental
issues. Most cases concern healthy parents in whom mosaicism is identified upon targeted testing of a genetic
defect that was initially detected in their children. A germline genetic defect affecting the euchromatin histone
methyltransferase 1 (EHMT1) gene causes Kleefstra syndrome, which is associated with the typical triad of distinct
facial appearance, (childhood) hypotonia, and intellectual disability. A high degree of psychopathology is associated
with this syndrome. A few parents with a mosaic EHMT1 mutation have been detected upon testing after a child
was diagnosed with a germline EHMT1 defect. At first glance, carriers of a mosaic EHMT1 mutation appeared to
function normally. However, recent studies have shown that de novo, postzygotic mutations in important
developmental genes significantly contribute to autism spectrum disorder (ASD). Therefore, we hypothesized
that EHMT1 mosaicism could cause neuropsychiatric defects. To investigate this, we performed a detailed
investigation of cognitive neuropsychiatric parameters in parents identified with EHMT1 mosaicism.
Methods: Three adults (two males, one female) with a genetically confirmed diagnosis of EHMT1 mosaicism
were examined by means of a battery of tests and observational instruments covering both neurocognitive
and psychiatric features. The battery included the following instruments: the Autism Diagnostic Observation
Schedule (ADOS), the mini Psychiatric Assessment Schedules for Adults with Developmental Disabilities (mini
PAS-ADD), the Vineland Adaptive Behavior Scales (VABS), and the Cambridge Neuropsychological Test Automated
Battery (CANTAB). These measures were compared with our previously reported data from Kleefstra syndrome patients
with confirmed (germline) EHMT1 defects.
Results: All three subjects achieved maximum total scores on the VABS, indicative of adequate (adaptive) functioning.
In all, scores above cutoff were found on the ADOS for ASD and on the mini PAS-ADD for major depressive disorder
(lifetime). Finally, results on the CANTAB showed impaired cognitive flexibility in all subjects.
Conclusion: Individuals with EHMT1 mosaicism seem to have increased vulnerability for developing severe
psychopathology, especially ASD and mood disorders. Although at first glance they appear to be well-adapted in
their daily functioning, they may experience significant psychiatric symptoms and show reduced cognitive flexibility in
comparison to the general population.
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Background
Kleefstra syndrome (KS; OMIM #610253) is caused
by haploinsufficiency of the euchromatin histone
methyltransferase 1 (EHMT1) gene located at chromo-
some 9q34.3. Almost all cases of KS are due to de novo
microdeletions or intragenic loss-of-function mutations in
this gene [1, 2]. So far, no inherited cases have been
reported, except for a few cases on the basis of parental
mosaicism. Mosaicism for EHMT1 defects appears to be
rare. At present, only four cases have been reported: three
with a 9q34.3 microdeletion [3, 4] and one with a splice-
site mutation in EHMT1 [5]. These carriers of a genetic
EHMT1 mosaicism were reported to function normally in
daily life. However, the focus of these reports was on the
genetic and somatic features of the subjects. No data was
presented on the possible psychopathology, which is the
most pronounced comorbidity in patients with KS caused
by a germline EHMT1 defect [6–9].
The full KS phenotype is characterized by the core triad
of intellectual disability (ID), (childhood) hypotonia, and
distinct facial features. Additional clinical features include
specific behavioral characteristics, heart and urogenital
defects, epilepsy, and overweight [1, 2, 10]. Recently, we
studied the specific profile of behavioral characteristics in
KS, which led us to conclude that KS patients are
extremely vulnerable to developing severe psychiatric
disorders. In our cohort, the prevalence of autism
spectrum disorder (ASD) is nearly 100% [6]. In addition,
we found high prevalence of mood disorders and psych-
otic disorders. Moreover, patients above the age of 18 years
in our cohort showed severe regression with a loss of at
least 30–50% of their initial functioning [6, 8, 11]. Interest-
ingly, recent studies have shown that de novo postzygotic
mutations (PZM) in important developmental genes
contribute to ASD [12, 13]. Based on this evidence, we set
out to investigate the presence of psychopathology in the
parents with an EHMT1 mosaicism.
In this study, we examined three subjects with EHMT1
mosaicism for the presence of psychopathology. All
three subjects are seemingly unaffected parents of chil-
dren diagnosed with KS caused by a germline EHMT1
defect. We hypothesized that individuals with EHMT1
mosaicism are vulnerable to psychopathology which may
have significant clinical consequences.
Methods
Participants
Subjects with EHMT1 mosaicism were invited by the
Department of Human Genetics, Radboud University
Medical Center, Nijmegen, the Netherlands, to partici-
pate in this study. Informed consent was obtained. The
regional medical ethical committee (medical research
ethics committee CMO/METC Arnhem-Nijmegen, the
Netherlands) approved the study (NL43187.091.13),
which was performed in full accordance with the Declar-
ation of Helsinki.
Subject characteristics are summarized in Table 1.
Mosaic pattern detection
In all three subjects, the presence of mosaicism was
detected upon carrier testing after the initial finding of a
deletion in 9q34 by genome-wide arrays in their respective
children. Subsequent confirmation by fluorescent in situ
hybridization (FISH) and/or multiplex ligation-dependent
probe amplification (MLPA) in blood or in additional
tissue was performed in all three subjects.
Instruments
The instruments that were used in this case study are
briefly described below. More extensive details can be
found in the study of Vermeulen et al. [6] where the in-
struments have been applied previously in a large cohort
of patients with the full KS phenotype.
The Autism Diagnostic Observation Schedule (ADOS)
is a semi-structured observational method to assess aut-
ism features [14, 15]. It is performed by a certified psych-
ologist or psychiatrist (in this cohort, the first author, KV)
and consists of four modules, based on the (developmen-
tal) age and language capacity of the participant. Module
4 is designed for normal functioning adults and was used
in the current study. A total cutoff score of 7 and above is
suspect for an ASD.
The Dutch version of the mini Psychiatric Assessment
Schedules for Adults with Developmental Disabilities (mini
PAS-ADD) is a psychometrically adequate interview for
the detection of psychiatric symptoms and disease in
persons with developmental disabilities [16, 17]. It consists
of 86 items on a 4-point scale: 0 (symptom not present) to
3 (symptom is severe). The interview is divided into seven
subscales: major depressive disorder (MDD), anxiety,
obsessive-compulsive disorder, hypomania/mania, psych-
osis, unspecified disorder, and autism. All criteria are based
on the International Classification of Diseases (ICD-10). In
this study, subjects were interviewed about themselves.
The Dutch adaptation of the Vineland Adaptive Behav-
ior Scales (VABS) [18] is a widely used clinical interview,
which determines the level of adaptive functioning. The
age-equivalent scores aid in classifying intellectual and
developmental disabilities. The VABS consists of three
domains: communication skills, daily living skills, and
social skills. This instrument has good reliability and
validity [19]. In this study, the subjects were interviewed
about themselves.
The Cambridge Neuropsychological Test Automated
Battery (CANTAB) is a tablet-based neuropsychological
test set comprising all major cognitive domains. Four
subtests of the CANTAB were performed in the follow-
ing sequence:
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1. The Motor Screening Test (MOT) is a training
procedure designed to introduce the subject to the
tablet touchscreen. In our cohort, it is also an
estimate to reactivity, which could not be tested
with an official reaction time test because of the
complexity of the latter (pushing a button instead of
the touch screen during the task).
2. The Pattern Recognition Memory (PRM) is a test of
visual pattern recognition memory in a two-alternative
forced choice discrimination paradigm. These patterns
are designed in such a way so that they cannot easily
be given verbal labels. This study presents the number
of correct responses.
3. The Intra-Extra Dimensional Test Shift (IED) is a
test of rule acquisition and reversal. Visual
discrimination, cognitive flexibility, and sustained
attention are tested. This study presents (1) total
errors, a measure of the subject’s efficiency in
attempting the test, and (2) the number of
completed stages.
4. Paired Associate Learning (PAL) assesses visual
memory and new learning. It consists of eight stages.
Table 1 Genetic, psychopathological, and neurocognitive subject characteristics of the subjects
Subject 1 Subject 2 Subject 3
Sex/age (years) Male/44 Female/43 Male/39
Genetic defect
[EHMT1 mosaicism]
∼ 60 kb deletion
exons 5–17 EHMT1
40% mosaicism in blood lymphocytes
and buccal swab
∼ 200 kb deletion
exons 1–5 EHMT1
80% mosaicism buccal swab
∼ 200 kb deletion
exon 1 EHMT1
60% mosaicism blood lymphocytes
VABS (maximum score)
Communication (134) 134 121 132
Daily living skills (184) 184 176 177
Socialization (132) 132 118 132
Raw score (450) 450 415 441
Mean developmental age in years > 12 > 12 > 12
ADOS module 4 (cutoff score)
Communication (2) 4 2 2
Social interaction (4) 7 10 9
Total score (7) 11 12 11
Classification Autism spectrum disorder Autism spectrum disorder Autism spectrum disorder
Mini PAS-ADD
Major depressive disorder Past Present and past Present and past
Anxiety disorder – Present and past –
(Hypo)mania – – –
Obsessive compulsive disorder – Present and past –
Psychosis – Present and past –
Unspecified disorder – – –
Autism spectrum disorder – – –
CANTAB *
MOT mean latency 85–90% 40–45% 80–85%
MOT error 70–75% 95–100% 40–45%
PRM 20–25% 0–5% 70–75%
IED error 30–35% 10–15% 10–15%
IED completed stages 15–20% 5–10% 10–15%
PAL 55–60% 0–5% 75–80%
VABS Vineland Adaptive Behavior Scales, mini PAS-ADD Psychiatric Assessment Schedules for Adults with Developmental Disabilities, CANTAB Cambridge
Neuropsychological Test Automated Battery, MOT Motor Screening Test, PRM Pattern Recognition Memory, IED Intra-Extra Dimensional, PAL Paired
Associate Learning
*The percentages represent the subjects’ performance compared to the normative group. For example, a subject score of 10% means that 90% of the normative
group has better scores on this item
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Each stage is composed of several trials, consisting
of the first presentation of the shape(s) and followed
by representation when the subject makes an error.
The clinical mode terminates after ten repeat
presentations. This study presents the total number
of errors.
Procedure
Subjects were visited at home. After obtaining informed
consent, the study procedure consisted of two clinical in-
terviews with the subjects (VABS and mini PAS-ADD),
followed by a semi-structured observation (ADOS) and
the tablet-based neurocognitive tests (CANTAB). These
procedures were performed by a certified psychiatrist
(KV).
Clinical reports
Subject 1 is a 44-year-old married male. He is a father of
two children; the youngest son was diagnosed with KS.
After finishing a higher professional education, he started
working as a data engineer. He does not report social or
communicative problems himself; meaningful social
contacts are limited, even with family members and
colleagues. He had a normal development. His medical
history includes an inguinal hernia and hydrocele in child-
hood, both of which were surgically corrected. The family
history does not mention any medical or developmental
problems. At physical examination, no typical facial
characteristics were observed.
Subject 2 is a 43-year-old female, mother of two chil-
dren, and her youngest daughter was diagnosed with KS.
The somatic characteristics of subject 2 and her youngest
daughter have been previously described, represented as
family 2 [3]. At the age of 13 years, the subject emigrated
from Morocco to the Netherlands. She experienced learn-
ing difficulties and did not finish high school. Besides
running the household, she started working as a care
assistant for elderly people. She was not able to take care
of her own financial administration, because of learning
difficulties. Her psychiatric history reported a MDD dur-
ing pregnancy for which fluoxetin was prescribed. Further
medical history mentioned three spontaneous abortions,
psoriasis, and nephritis. Additionally, she experiences
sleep disturbances comprising apneas and frequent
awakenings during the night.
Her social network was limited to her family. She had
no friends and experienced problems in initiating and
maintaining contacts and conversations. Small talk was
difficult for her. At the time of examination, she was
divorced and not able to work due to mental health
problems, consisting of problems in social reciprocity,
reactive depressive complaints, and overstimulation and
burnout.
At the time of our investigations, she experienced a
second major depressive episode with psychotic features
(imperative hallucinations and delusions). The imperative
hallucinations had led to a suicide attempt. Her general
practitioner was informed after our examination, and
intensive outreaching care was suggested based on our
observation. Physical examination of this subject at the
age of 43 years showed obesity and minor dysmorphic
features as previously described, including a hypoplastic
midface, small upslanting palpebral fissures, depressed
nasal root, and anteverted nares.
Subject 3 is a 39-year-old male with three children: the
second child was diagnosed with KS. There is no further
family history of somatic or neuropsychiatric disorders.
After finishing primary school, he struggled to finish
high school (practical education level) because of learn-
ing disabilities. He went through different jobs, but at
the time of the current evaluation, he was not able to
work due to his impaired somatic and mental health. He
lives an isolated life, together with his wife and children.
Despite his social isolation, the patient did not experi-
ence any problems in social behavior.
His birth was complicated by a forceps delivery. The
remaining medical history revealed atrial fibrillation, knee
surgery, tonsillectomy, tympanostomy, and mild auditory
and visual impairment. Pharmacotherapy started after the
atrial fibrillation was diagnosed and comprised the follow-
ing: metoprolol, acenocoumarol, simvastatin, and perindo-
pril. Physical examination at the age of 39 years showed
obesity, an occipito-frontal circumference of 59 cm (nearly
+ 1 SD), and minor dysmorphic features including a hypo-
plastic midface and synophrys.
Genetic analysis
Subject 1: After the detection of an intragenic EHMT1
deletion in the son by routine array analysis, we per-
formed an MLPA (kit P340-A1, MRC-Holland,
Amsterdam, The Netherlands) analysis to confirm the
deletion in subject 1. We detected an intragenic deletion
of exons 5–17 of EHMT1 in DNA from both blood lym-
phocytes and a buccal swab sample, with a mosaicism of
40%. In cultured fibroblasts, the level of mosaicism was
15–20% of cells carrying the deletion.
Subject 2: Results were presented in more detail in a
previous study [3]. In summary, genome-wide array ana-
lysis on DNA from the daughter revealed an interstitial
deletion of ~ 200 kb in 9q34.3 encompassing at least the
first five exons of the EHMT1 gene. Carrier testing by
array in both parents showed that this deletion was inher-
ited from subject 2 (the mother), but her array results
showed a less pronounced loss, suggestive of mosaicism.
Interphase FISH analysis with two different FISH
probes on a buccal swab sample from subject 2 showed
the deletion in 80% of her cells (50–55 cells analyzed),
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indicating that she is a mosaic carrier of the 9q34.3
deletion: .nuc ish del(9)(q34.3q34.3)(RP11_417A4-)[37/
55],(RP13_467E5-)[45/50].
Subject 3: After the detection of a 9q34.3 deletion in the
son (arr [hg 19] 9q34.3(140350924 140551108)× 1), the
array analysis on DNA from subject 3 suggested the pres-
ence of a mosaic deletion in 9q34.3. Subsequent FISH
analyses on blood lymphocytes showed an abnormal
signal pattern in 29 of 50 cells analyzed, suggesting 60%
mosaicism: ish del(9)(q34.3q34.3)(RP11-48C7-)[29/50].
Results
The genetic, psychopathological, and neurocognitive
characteristics are presented in Table 1.
Psychopathological and neurocognitive studies
The developmental age of all three mosaic carriers was
12 years or older. This maximum score on the clinical
interview VABS is in line with the developmental age of
the general population. Additionally, all subjects fulfilled
the diagnostic criteria for ASD and MDD either currently
and/or in the past. In contrast to the ADOS, the mini
PAS-ADD did not formally determine ASD as the total
subscale scores were just below the cutoff score. Notwith-
standing, ASD items scored in the mini PAS-ADD were
similar to the clinical observations of the ADOS. During
the clinical observation, all participants scored on limited
eye contact and minimum use of emotional gestures,
when testing was focused on the communication. For
social interaction, all three showed impaired social reci-
procity, a limited range of facial expressed emotions, and
an inadequate description of their role in social relations.
In addition to estimating the degree of psychopath-
ology, we used the CANTAB to measure several cogni-
tive functions of our subjects. The percentages represent
the subjects’ performance compared to the normative
group with the same sex and age. Subject 1 had low
scores on the PRM and IED. Subject 2 had overall low
scores on the tests. Subject 3 experienced problems with
the IED. Detailed results are presented in Table 1; all
IED scores were lower than 35% of the peer group, indi-
cating an impaired mental flexibility in all three subjects.
Discussion
In this report, we describe the consequences of EHMT1
mosaicism on psychopathology in three adult subjects.
The three seemingly unaffected parents included in this
study had been referred to the clinical genetics depart-
ment only because of the diagnostic trajectory of each par-
ent’s respective child. The discovery of EHMT1 mosaicism
in these subjects was unexpected [3–5]. The degree of
mosaicism that was measured in different tissues varied
from 15 to 40% (subject 1) to 80% (subject 2). It is difficult
to predict the clinical consequences of mosaicism, as the
patterns and distribution of abnormal cells can vary widely
between different tissues, depending on the timing of the
mutation events [20]. Despite this predicted variation, all
three subjects had an ASD, a (prior) MDD, and other as-
sociated neurocognitive dysfunctions. Some features that
can be seen in patients with a germline EHMT1 mutation
had a variable occurrence in the mosaic individuals. The
results are indicative of a vulnerability to develop severe
psychiatric disorders that carriers of an EHMT1 mosaic
mutation possess. This correlates with the high prevalence
of psychopathology, which has been reported for individ-
uals with the full KS phenotype due to a germline EHMT1
mutation [6, 8, 21]. Based on the ADOS test, all mosaic
subjects met the criteria for ASD and all had a (prior)
MDD. This is further corroborated by our findings on the
CANTAB. All subjects showed weaknesses in perform-
ance on the IED, which is suggestive of cognitive inflex-
ibility. This might be related to the set-shifting problems
often seen in subjects with ASD, although findings on
executive function deficits in adults with ASD were incon-
sistent [22]. These deficiencies on the IED are on the con-
tinuum compared with a significant high dropout on the
IED in our previous research on subjects with the full KS
phenotype (unpublished data). Subject 3 had no other
deviating scores compared to his norm group. Subject 1
showed performance problems on the PRM, but we could
not clearly link this to his clinical profile. Subject 2 had
low scores on all tasks, most likely due to (a combination
of) her learning and mood problems.
Psychopathology has a direct impact on adaptive func-
tioning. The adaptive behavior measured with the VABS
implies a developmental age above 12 years, consistent
with adult functioning, for all of our subjects. Neverthe-
less, all three of them struggle to fulfill their role in
society, most likely as a direct consequence of their neuro-
developmental problems. They became socially isolated
and experienced difficulties in finding the right type of
education and employment that would suit their strengths
and weaknesses. Therefore, the clinical relevance for diag-
nosing these subjects with EHMT1 mosaicism and conse-
quent neuropsychiatric assessment is significant. Optimal
treatment of the psychopathology may improve daily func-
tioning and positively influence the well-being of the indi-
viduals treated and their families, including the child with
KS, as well as their participation in society. Based on our
findings, personalized psychiatric evaluation and treat-
ment should be considered for subjects diagnosed with
EHMT1 mosaicism. The diagnostic procedure should
include a special attention to ASD and mood disorders.
Furthermore, these cases illustrate that presence of mosaic
deletions could potentially be missed, since the genetic
defects were only discovered during the diagnostic phase
of the children with the full KS phenotype. None of the
subjects had been referred to a medical specialist for their
de Boer et al. Molecular Autism  (2018) 9:5 Page 5 of 7
own psychiatric problems prior to our studies. These
subjects tend to have a more subtle presentation, but this
can nevertheless cause impaired (social) functioning.
Therefore, our study also demonstrates that genetic ana-
lysis should be considered in patients with a psychiatric
disorder and other characteristics of KS without the
classic appearance.
Despite the similarities in psychopathology between
our subjects, the consequences of mosaicism in general
are widespread and unique for each individual [23]. The
phenotypic expression of somatic mosaicism has been
investigated and reported in several studies including
mosaic trisomy 21 (Down syndrome) and mosaic fragile
X syndrome [24, 25]. These studies show severe pheno-
typic expression, as well as somatic mosaicism without
clinical consequences. The expression of the behavioral
phenotype is also variable. In mosaic trisomy 21, for ex-
ample, the social adaptive skills were significantly better
in the subjects with a mosaicism compared to non-mo-
saic subjects with Down syndrome. However, the intel-
lectual performance did not relate to the level of
mosaicism [24]. This necessitates interpretative caution,
especially since we assessed the psychopathology of only
three subjects with an EHMT1 mosaicism and each had
different levels of mosaic expression. Interestingly, in
recent studies, it was shown that rare postzygotic muta-
tions in important developmental genes contribute
significantly to ASD [12, 13]. Our present results
obtained for three ASD subjects with such a rare mosaic
defect in EHMT1 are in line with these reports. EHMT1
is an important developmental gene that is extremely
intolerant to loss-of-function mutations (http://exac.-
broadinstitute.org) [26]. Further clinical studies are war-
ranted to provide more insight into the wide spectrum
of the EHMT1 mosaicism, although the extremely low
prevalence of such mosaic defects hampers the careful
collection of symptoms in larger cohorts. For future
research, we recommend to include more specific mea-
sures on IQ, ASD, and mood disorders in subjects with
an EHMT1 mosaicism. These measures should be in
addition to a (semi)structured clinical observation as
people with neurodevelopmental disorders, like ASD, are
more likely to have deviating scores on questionnaires
[27, 28]. Thus, clinical interviews and observations
should always be performed to gain a more comprehen-
sive and objective insight into the psychopathology.
Conclusion
Subjects with EHMT1 mosaicism seem vulnerable to
developing psychiatric disorders, especially ASD and
mood disorders. However, since the behavioral outcome
of mosaicism is unpredictable, these results should be
interpreted with caution. Based on our findings in this
small but unique cohort, we recommend screening
subjects with an EHMT1 mosaicism for psychopath-
ology. In our experience, multidisciplinary care, combin-
ing expertise in psychiatry, clinical genetics, and clinical
neuropsychology, is of additional value in these complex
cases where a broad perspective is required. Ideally, a
careful diagnostic assessment of psychopathology, cogni-
tion, and physical health should be performed to provide
an integrative diagnosis. Deficits in daily functioning and
behavioral problems may well be a result of an under-
lying genetic or otherwise somatic cause, which is often
not clearly present. Clinical considerations should there-
fore include the possibility of a genetic mosaicism in
parents who have one or more children with a neurode-
velopmental disorder of genetic origin and a typical
combination of complaints, as illustrated in this study.
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